• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program

    9/19/23 6:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • In its second season, the 2023 Dexcom U roster consists of 20 athletes with diabetes across 10 sports, 20 colleges, and includes 11 new team members
    • Expanded program gives these collegiate athletes a platform to share their stories, serve as role models and inspire other people with diabetes

    DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of Dexcom U, the first-ever NIL (name, image, likeness) program exclusively for college athletes with diabetes, which had its inaugural season last year.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919150027/en/

    Dexcom U kicks off 2023 season with expanded roster of athletes with diabetes, building on first-of-its-kind NIL program. (Graphic: Business Wire)

    Dexcom U kicks off 2023 season with expanded roster of athletes with diabetes, building on first-of-its-kind NIL program. (Graphic: Business Wire)

    Dexcom U is a unique NIL program that was created in response to a 2022 survey which found that improving representation for people with diabetes can inspire future generations of athletes living with the condition. With about 17% of student athletes at Division I institutions participating in NIL activities in 20221 and that number expected to grow, Dexcom U is still the only NIL program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own.

    Throughout the last year, athletes on the Dexcom U inaugural roster participated in 381 collegiate competitions with the help of Dexcom continuous glucose monitoring (CGM) technology. The impact of the program is set to expand in 2023 as the roster size grows by 43%.

    "In response to last year's launch, we heard from parents of young children, coaches and athletes with diabetes who felt seen through the stories of Dexcom U athletes," said Teri Lawver, Executive Vice President, Chief Commercial Officer at Dexcom. "We're thrilled to expand the program in year two and continue celebrating these inspirational collegiate athletes while proving that diabetes does not have to hold you back."

    Dexcom not only understands the pivotal role technology plays in helping athletes with diabetes feel and perform at their best, but also the importance of support from others who understand what it's like to strive for athletic excellence while managing diabetes. A Dexcom survey showed nearly half (48%) of adults with Type 1 diabetes and parents to children with diabetes believe that being aware of a professional or top amateur athlete or celebrity with Type 1 diabetes would be very beneficial for a newly diagnosed individual,2 which is why mentorship continues to be a cornerstone of the program.

    The Dexcom U 2023 roster consists of 20 athletes, including 11 new teammates, all who rely on Dexcom CGM to track their glucose levels* and manage their diabetes:

    • Amber Jackson, Track & Field, University of Louisville
    • Ava DeStefon, Cheerleading, Clemson University
    • Beau Corrales, Football, Texas State University
    • Bri Carrasquillo, Lacrosse, Yale University
    • Bryce Frederick, Baseball, Towson University
    • Cade Brown, Baseball, Murray State University
    • Caleb Fauria, Football, University of Colorado
    • Dante Vasquez, Football, Springfield College
    • Isaac Traudt, Basketball, Creighton University
    • Jaime Ferrer, Baseball, Florida State University
    • Jaxon Dowell, Golf, University of Oklahoma
    • Jessica Walter, Softball, Providence College
    • Joshua Meriwether, Football, Tennessee State University
    • Leo Giannoni, Baseball, Columbus State University
    • Madison Moraja, Track & Field, North Carolina State University
    • Marlee Fray, Soccer, University of Texas at San Antonio
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Paris Husic, Track & Field, Wake Forest University
    • Raegan Lantz, Volleyball, Miami University
    • Tristan Wakefield, Rowing, Syracuse University

    "I'm elated to come back for my second year and continue to show I can accomplish anything while living with diabetes," said Bri Carrasquillo, Lacrosse player at Yale University and second-year member of Dexcom U. "My Dexcom CGM allows me to play at my highest level, while giving me, my coaches and family peace of mind by tracking my glucose levels through the Follow app.† I feel it's important to educate others about the tools available that have made such a difference in my diabetes management."

    As part of the program, Dexcom has created educational resources for athletes with diabetes as well as for parents, coaches and teammates so they can better understand the disease and how to support the people with diabetes in their lives. Resources include first-hand advice from Dexcom U athletes as well as tips for managing diabetes, exercise and mental wellbeing – on and off the field.

    "It's a privilege to join such a special group of athletes and shed light on the important mission of Dexcom U," said Dante Vasquez, football player Springfield College and first-year member of the program. "Not only does being part of Dexcom U give me confidence to perform at my highest levels with my Dexcom G7, but it empowers me to be a mentor and inspire the next generation of athletes with diabetes."

    To learn more about Dexcom U and access the educational resources, visit dexcom.com/DexcomU.

    About Dexcom, Inc.

    Dexcom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit Dexcom.com.

    1 Student-Athlete Insights, January 2023

    2 Dexcom, U.S. data on file, September 2022

    * For a list of compatible devices, visit www.dexcom.com/compatibility.

    † Compatible smartphone and internet connection required

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230919150027/en/

    Get the next $DXCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    3/12/2024$165.00Outperform
    RBC Capital Mkts
    5/30/2023$131.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Dexcom with a new price target

      Mizuho initiated coverage of Dexcom with a rating of Outperform and set a new price target of $85.00

      4/10/25 12:40:59 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Dexcom from Neutral to Buy and set a new price target of $115.00 from $85.00 previously

      2/3/25 7:06:44 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Dexcom from Neutral to Outperform and set a new price target of $104.00 from $86.00 previously

      1/16/25 7:42:21 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    See more

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Dexcom Appoints Renée Galá to Board of Directors

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of patients and their families. In this role for Jazz Pharmaceuticals, Ms. Galá oversees global business operations including commer

      3/10/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/13/24 5:02:33 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/23 11:16:37 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/22 3:43:37 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Coleman Jon

      3 - DEXCOM INC (0001093557) (Issuer)

      3/31/25 6:57:22 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Director Heller Bridgette P sold $24,756 worth of shares (352 units at $70.33), decreasing direct ownership by 2% to 22,997 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      3/19/25 5:02:07 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Operating Officer Leach Jacob Steven sold $990,670 worth of shares (14,076 units at $70.38), decreasing direct ownership by 4% to 313,497 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      3/14/25 5:25:36 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

      Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C

      4/10/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Financials

    Live finance-specific insights

    See more
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start

      4/3/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-GAAP operating income* of $209.5 million or 18.8% of reported revenue, a decrease of 470 basis points compared to the fourth quar

      2/13/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by DexCom Inc.

      S-8 - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:18:23 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:10:04 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care